Clinical Trials
14 trialsNCT03304639 2026-05-13
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03599713 2025-08-05
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Incyte Corporation
Phase 2 Completed
NCT02196961 2025-04-09
ADMEC-O
University Hospital, Essen
Phase 2 Completed
NCT02819843 2025-01-29
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04393753 2024-05-08
MERKLIN2
4SC AG
Phase 2 Completed
NCT02155647 2024-03-13
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
EMD Serono
Phase 2 Completed
NCT02267603 2023-07-05
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01440816 2023-05-15
MCC
OncoSec Medical Incorporated
Phase 2 Completed
NCT01013779 2022-11-18
MP3
Trans Tasman Radiation Oncology Group
Phase 2 Completed
NCT02351128 2017-10-18
PHRC-Merkel
University Hospital, Grenoble
Phase 2 Completed
NCT00004922 2013-06-19
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00079131 2013-06-04
Oblimersen in Treating Patients With Merkel Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00068783 2013-02-28
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003549 2012-10-08
S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
SWOG Cancer Research Network
Phase 2 Completed